Despite impressive data supporting HMA/Venetoclax, its application in younger, fit patients must be cautious. The pivotal VIALE-A trial excluded key subgroups like FLT3, core binding factor, and certain NPM1 patients, for whom intensive chemotherapy remains the standard.

When a patient progresses on a covalent BTK inhibitor, using venetoclax next offers a strategic advantage beyond its efficacy. It may reshape the disease's clonal architecture by suppressing BTK-resistant clones, potentially restoring or improving the benefit from a different BTK inhibitor used later in the treatment course.

The development of regimens like SAVE (oral decitabine, venetoclax, revumenib) demonstrates that complex, effective combination therapies for acute leukemia can be administered entirely orally. This marks a paradigm shift towards more convenient, less burdensome treatment that reduces time in the hospital or clinic.

The FLAG-IDA plus venetoclax regimen achieves very high MRD-negative remission rates. However, its similar efficacy in both frontline and first salvage settings suggests it might be more strategically deployed as a salvage therapy, avoiding its high toxicity in all patients upfront.

The IDH1 inhibitor olutasidenib demonstrates a much longer duration of response than ivosidenib. One hypothesis is that olutasidenib's weaker affinity for wild-type IDH1 makes it a more selective inhibitor of the mutant protein, leading to more durable disease control.

When an AML patient presents with multiple targetable mutations (FLT3, NPM1, IDH), clinicians follow a treatment hierarchy. FLT3-targeted therapy is typically the first choice due to its aggressive phenotype. Menin inhibitors for NPM1 are next, followed by IDH inhibitors, guiding treatment decisions in complex cases.

Similar to FLT3 inhibitors like midostaurin, which failed in the relapsed setting but succeeded upfront, menin inhibitors are expected to show dramatically better efficacy when combined with standard induction or HMA/Venetoclax in newly diagnosed patients.

While adding a menin inhibitor to the azacitidine/venetoclax doublet for older/unfit AML patients increases response rates, it leaves little reserve for marrow function. This can lead to increased risk of early, fatal complications like infection or bleeding, requiring careful dose management.

In treating elderly AML patients, safety is paramount. The current standard, venetoclax, has an early (30-60 day) mortality rate of around 7%. Early data for mesutoclax shows zero early deaths in over 40 patients. This, combined with shorter durations of severe cytopenias, suggests a superior safety profile that could be a more important clinical differentiator than efficacy alone.